In every crypto cycle, capital does not move all at once. It rotates. Large names slow down first. Then attention shif ...

Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in ...

Company on track to report topline results early in the second quarter of 2026Second planned Data and Safety Monitoring Board ...

XLM shows recovery potential with inverse head and shoulders pattern, positive money flows, and $986M RWA growth despite 34% ...

TDK has announced the release of the TDK‑Lambda TPS4500 series of industrial AC‑DC power supplies, offering a rated output of ...

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment — — Savolitinib ...

ASPIRO is the first multi-patient, multi-center clinical trial of an autologous cell therapy for Parkinson's disease. It is evaluating safety, tolerability, and preliminary efficacy of ANPD001 in ...

Myanmar's junta opened polls on Sunday in the second phase of elections, continuing a vote democracy watchdogs say is letting ...

At 78 years old, Maria has high blood pressure and needs to take seven different medications throughout the day at specific ...

By tracking biometrics like temperature, respiratory rate and heart rate, the Oura Ring can catch early signs of physical ...

InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.

SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpointsThe overall safety results in this study were consistent with the established safety profile ...